Clinical Trials Arena on MSN
Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer
The primary efficacy analysis showed the gedatolisib triplet led to statistically significant and clinically meaningful PFS ...
The FDA has approved the first proteolysis-targeting chimera for any oncologic indication. Vepdegestrant (Veppanu, Arvinas ...
“Medical Journeys” is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
After you’re diagnosed with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer, your doctor’s goal is to build a treatment plan that gives you the best chance of controlling your ...
Enhertu showed better outcomes in HR-positive, HER2-negative breast cancer, while Trodelvy was more effective in HR-negative, HER2-null tumors when used first. Real-world data from over 4,000 patients ...
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results